Upgrader Therapeutics is a startup developing a proprietary targeted protein degrader platform based on modular biologics. Its technology is designed to address disease-driving proteins that remain difficult to drug with conventional approaches, including small molecules, PROTACs, and molecular glues. The company is based at BioLabs Philadelphia, where it is advancing early proof-of-concept work.